2011
DOI: 10.1185/03007995.2011.639752
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Our MICD estimate for an improvement in T25FW is close to previous estimates of 20% change. Dalfampridine may improve walking speed in a considerable proportion of patients by a clinically relevant amount.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
66
2

Year Published

2013
2013
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 74 publications
(72 citation statements)
references
References 19 publications
4
66
2
Order By: Relevance
“…Importantly, more than half of the D-ER responders (59%) had an increase in walking speed of ≥20%, which is considered a clinically meaningful change. [22][23][24][25]30 The average change in the patient-reported MSWS-12 score among D-ER responders also exceeded the range of estimated values of the minimal clinically important difference (4.0-5.7 points), 31 indicating that the improvements in walking are clinically relevant from the patient's perspective.…”
Section: Safetymentioning
confidence: 89%
“…Importantly, more than half of the D-ER responders (59%) had an increase in walking speed of ≥20%, which is considered a clinically meaningful change. [22][23][24][25]30 The average change in the patient-reported MSWS-12 score among D-ER responders also exceeded the range of estimated values of the minimal clinically important difference (4.0-5.7 points), 31 indicating that the improvements in walking are clinically relevant from the patient's perspective.…”
Section: Safetymentioning
confidence: 89%
“…The average improvement in walking speed of approximately 25% [Goodman et al 2009[Goodman et al , 2010 seems highly clinical relevant [Coleman et al 2012]. The responder concept can be debated though because the degree of increase in walking speed is not a criterion for response.…”
Section: Discussionmentioning
confidence: 99%
“…Anchored to the CGI term 'minimally improved' subjects had a mean improvement of 0.36 ft/s or a 17.2% relative change in walking speed from a baseline value of 2.1 ft/s. Using the distributionbased approach the minimally important clinical difference was estimated to be 0.35-0.37 ft/s [Coleman et al 2012].…”
Section: Sustained-release 4-aminopyridine (Fampridine)mentioning
confidence: 99%
“…The minimal clinically important difference for this measure has been noted in the literature to be approximately 20%. 25 Coleman et al, 26 in their study of the effects of dalfampridine on gait speed for people with MS, suggested that a minimal clinically important dif- Table 1. Detailed results for all the outcome measures are shown in Table 2.…”
Section: Gait Performancementioning
confidence: 99%